Abstract
Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Current Topics in Medicinal Chemistry
Title:Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease
Volume: 13 Issue: 15
Author(s): Ana Martinez, Daniel I. Perez and Carmen Gil
Affiliation:
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Abstract: Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Export Options
About this article
Cite this article as:
Martinez Ana, Perez I. Daniel and Gil Carmen, Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2013; 13 (15) . https://dx.doi.org/10.2174/15680266113139990138
DOI https://dx.doi.org/10.2174/15680266113139990138 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitory Mechanisms of Antibiotics Targeting Elongation Factor Tu
Current Protein & Peptide Science Postpartum Depression in Women with the FMR1 Premutation
Current Psychiatry Reviews Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Addressing Depression and Suicidality in the College Population
Current Psychopharmacology Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer’s Disease
Current Alzheimer Research Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
Current Pharmaceutical Design Anti-inflammatory Activity of Extra Virgin Olive Oil Polyphenols: Which Role in the Prevention and Treatment of Immune-Mediated Inflammatory Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry The Role of Cytokine Network in the Pathophysiology of Schizophrenia
Current Psychiatry Reviews Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Respiratory Viruses, Eosinophil Activation, and Early Allergen Sensitization - Early Life Predictors of Persistent Wheezing and Asthma
Current Pediatric Reviews Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Endogenous Regulation of Neural Stem Cells in the Adult Mammalian Brain
Central Nervous System Agents in Medicinal Chemistry Anesthetics Act in Quantum Channels in Brain Microtubules to Prevent Consciousness
Current Topics in Medicinal Chemistry Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design